Skip to main content

Table 4 Multivariable analysis of outcomes in unweighted, greedy-matching, and stabilized inverse probability of treatment–weighed samples

From: Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab

Outcomes

Unweighted sample

Greedy matching

Stabilized IPTW

(n = 410)

(n = 231)

(n = 325)

Coef.a

95%CI of Coef

Coef.a

95%CI of Coef

Coef.a

95%CI of Coef

TSQM

Effectiveness

 − 2.255

(− 5.728, 1.218)

 − 1.557

(− 4.914, 1.800)

 − 0.18

(− 3.398, 3.038)

Side effectsb

 − 0.642

(− 1.45, 0.166)

 − 2.184

(− 5.081, 0.713)

 − 0.655

(− 1.466, 0.156)

Convenience

4.467

(1.127, 7.807)

3.763

(0.290, 7.236)

5.256

(2.149, 8.363)

Global satisfaction

 − 3.129

(− 7.169, 0.911)

 − 2.977

(− 7.062, 1.108)

 − 1.683

(− 5.421, 2.055)

EQ-VAS

 − 0.656

(− 5.581, 4.269)

0.027

(− 5.345, 5.399)

 − 2.661

(− 7.200, 1.878)

EQ-5Dc

0.191

(− 0.370, 0.752)

0.540

(− 0.215, 1.295)(e)

0.246

(− 0.293, 0.785)(h)

  1. aThe difference in outcomes between tofacitinib and adalimumab (a reference) estimated by multivariable analyses with performed by adjusting all variables for demographic and clinical characteristics, such as age, sex, CCI score, and disease duration
  2. bWhether TSQM (side effects) is 100 or not
  3. cEQ-5D < median or EQ-5D ≥ median
  4. IPTW inverse probability of treatment weighting, n number, Coef. coefficient, CI confidence interval, TSQM Treatment Satisfaction Questionnaire for Medication, EQ EuroQol, VAS visual analog scale, EQ-5D EuroQol-5-Dimension